Impact of methylation of the p16\textsuperscript{INK4a} gene on the prognosis of head and neck squamous cell carcinoma patients

Eui-Hoon Lee, Dae-Seok Hwang, Sang-Hun Shin, Uk-Kyu Kim, In-Kyo Chung, Yong-Deok Kim
Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, Yangsan, Korea

Abstract (J Korean Assoc Oral Maxillofac Surg 2012;38:101-9)

Objectives: The inactivation of the tumor suppressor gene p16\textsuperscript{INK4a} plays an important role in the development of malignant tumors, including oral squamous cell carcinoma. The p16 gene is involved in the p16/cyclin-dependent kinase Retinoblastoma (Rb) gene pathway of cell cycle control. The p16 protein is considered a negative regulator of this pathway. The p16 gene encodes an inhibitor of cyclin-dependent kinases 4 and 6 which regulate the phosphorylation of the retinoblastoma gene and G1 to S phase transition in the cell cycle. However, the p16 gene can lose its functionality through point mutations, loss of heterozygosity or methylation of its promoter region.

Materials and Methods: In this study, the authors analyzed the correlation between various clinicopathological findings—patient age, gender and smoking, disease recurrence, tumor size, stage, and differentiation—and p16 protein expression or p16 promoter hypermethylation in 59 cases of head and neck squamous cell carcinoma.

Results: The results revealed p16 protein expression and p16 promoter hypermethylation in 28 cases (47.5%) and 21 cases (35.6%), respectively, of head and neck squamous cell carcinoma. However, neither p16 protein expression nor p16 promoter hypermethylation had any statistical influence on clinicopathological findings or survival rate.

Conclusion: This data, and a review of the literature, suggest that p16 promoter hypermethylation cannot yet be used as an independent prognostic factor influencing carcinogenesis, but must be considered as an important factor along with other genetic alterations affecting the pRb pathway.

Key words: Methylation, Epigenomics, Prognosis, Neoplasms

[paper submitted 2011. 12. 14 / revised 2012. 2. 9 / accepted 2012. 3. 6]

I. Introduction

Tumors develop when the balance between oncogenes that induce tumors and tumor suppressor genes that repress them is disturbed. A normal cell transforms into a cancer cell when various genetic modifications take place; these lessen the control on cell cycles and lead to abnormal cell growth, which gives rise to tumors.

Previously, such control mechanisms were known to be affected by the change in DNA sequence and recombination, which cause a change in phenotype; nowadays, however, it is known that gene function may change without DNA sequence modifications, and that this change is passed on from parents to offspring. Epigenetics is a new field of study that investigates whether such change in gene function occurs without DNA sequence modifications and includes various modification processes such as DNA acetylation, methylation, phosphorylation, and ubiquitination. Well-known studies are those exploring the gene control mechanism concerning DNA methylation\textsuperscript{1}.

Numerous new findings are being made in the studies on tumors through epigenetics, including genetic variations in cells that express tumors. In a general genetic aspect, the mutation of DNA base is an important phenomenon; from an epigenetic viewpoint, however, the methylation process—which is the attachment of a methyl group to the base by a DNA methyltransferase (DNMT)—is significant\textsuperscript{1,2}. This process takes place only when a cytosine (C) is followed...
by a guanine (G), which is called CpG when the two bases are situated next to each other in a human genome DNA sequence; when CpGs are densely located, such is called a CpG island. This CpG island is located near the promoter area that controls the transcription process of the DNA. In particular, cytosine tends to be methylated, with 3-4% of the total cytosine of the human genome being methylated. Although it differs according to the type of tumor, in the development of a malignant tumor, oncogenes are activated after hypomethylation, whereas tumor suppressor genes are inactivated with hypermethylation. Studies report that this change in methylation is associated with the development of tumor.

One of the tumor suppressor genes, p16\(^{INK4a}\) (Inhibitor of cyclin-dependent kinase 4/6), encodes p16 proteins. The promoter area for the p16\(^{INK4a}\) gene includes the DNA sequence for the production of protein p16. The inactivation of this gene plays an important role in the development of a malignant tumor. The loss of p16 results from point mutation\(^4\), loss of heterozygosity (LOH)\(^5\), or hypermethylation\(^1\) of the promoter area. In this study, we investigated the presence of p16 protein and hypermethylation that inactivates the p16\(^{INK4a}\) gene in patients with head and neck squamous cell carcinoma in a retrospective design and compared it with the clinical findings of the tumor, recurrence, and survival rate. Specifically, we tried to determine whether epigenetic gene modifications have a direct effect on protein expression and decide whether the methylation of the tumor suppressor gene, p16, affects the prognosis of head and neck squamous cell carcinoma.

II. Materials and Methods

1. Materials

Tissue samples of 59 patients with head and neck squamous cell carcinoma and who had been diagnosed, operated, and subjected to post-operative evaluations at the Department of Oral and Maxillofacial Surgery, Pusan National University were used for the immunohistochemical tests of p16 protein and investigation of methylation of the p16\(^{INK4a}\) gene. The tissue was fixed with formalin and embedded in paraffin and stored in the Department of Pathology, Pusan National University Hospital. There were 15 women and 44 men, with mean age of 61.8 years (range: 28-86 years). The tumor sample was taken from a biopsy done before the initiation of treatment. All diagnoses were made based on samples with H&E staining along with histopathological tests.

2. Clinical and histopathological tests

The age of the patient, tumor location and size (4 grades: less than 2 cm, less than 4 cm, more than 4 cm, and invasion into adjacent structures), existence of smoking habit (+ vs -), recurrence (+ vs -), level of differentiation (well, moderate, or poor), and pathological stage (stage I-stage IV: American Joint Committee on Cancer [AJCC]\(^6\) 6th edition) were investigated and grouped for comparison with the expression of p16 protein and methylation of the p16\(^{INK4a}\) gene. Survival rate was determined in all cases, with observation period of 0.5-86 months (mean: 26.8 months). The size of the tumor was judged and grouped based on visual inspection on the first visit and computed tomography (CT) and magnetic resonance imaging (MRI) images, with pathological staging and grouping done based on general clinical examinations along with visual inspection on the first visit, chest radiographs, laboratory findings, CT and MRI images, location and size of lymph, and occurrence of metastasis. The correlation between the p16\(^{INK4a}\) gene and smoking as a major carcinogenic factor of intraoral cancer was also investigated.

3. Immunohistochemical tests

Immunohistochemical tests were done by gaining 4-μm thick sections of the paraffin-embedded tissues and attaching the tissue to a poly-L-lysine-coated slide and heating in an 80°C oven for 15 minutes and then removing the paraffin by treating for 2 minutes for 4 times at room temperature with xylene and soaking in numerous stages of alcohol and rehydrating with distilled water. To recover antigenicity, the sample was soaked in 10% citrate butter and boiled in a microwave oven for 10 minutes, and then made to stand at room temperature for 20 minutes followed by washing with 45°C buffered solution for 3 minutes thrice. Afterward, to remove intrinsic tissue peroxidase, the tissue was left in 3% H\(_2\)O\(_2\) solution for 5 minutes. The sample was then washed with buffered solution thrice, and non-immunologic goat serum (Zymed Laboratory Inc., San Francisco, CA, USA) was applied to remove the linkage of nonspecific proteins. The sample was left overnight at 4°C to react with p16 (PharMingen, San Diego, CA, USA) as the primary antibody. The secondary antibody- anti-mouse IgG human monoclonal antibody (NeoMarkers, Fremont, CA, USA)- was then applied for 10 minutes. The samples were washed...
with buffered solution for 3 minutes thrice and treated with a Streptavidin-biotin peroxidase kit (Zymed Laboratory, Inc., San Francisco, CA, USA) at 45°C for 10 minutes to induce biotin-streptavidin specific linkage. The sample was then washed again, and color reaction was induced with 3-amino-9-ethylcarbazole for 10 minutes; counterstaining was done with hematoxylin before mounting and observing with a light microscope. The palatine tonsil tissue was used as positive control, and tissues that were not treated with the primary antibody were used as negative control.

Each case was scored according to the decided criteria\textsuperscript{7-9}. For example, if the nucleus of the tumor cells was evenly stained throughout the entire tumor, p16 expression was considered normal. In contrast, the expression of p16 was deemed to have decreased in that tumor when the nuclei of the mixed non-tumor cells were stained and those of the tumor cells were only partially stained or the nuclei of the mixed non-tumor cells were stained but those of the stained tumor cells were missing.

4. DNA extraction from tissue samples

Genomic DNA was extracted with a standardized proteinase K digestion and the phenol/chloroform extraction method. The tissue was taken from tumor locations with distinct pathohistological characteristics of squamous cell carcinoma, and DNA was extracted from this sample for PCG assay.

5. Bisulphite modification and methylation–specific polymerase chain reaction (MSP)

Bisulphite modification was done with a DNA modification kit (Intergen, Purchase, NY, USA) by following the manufacturer’s instructions. The modified DNA was used for MSP.

Polymerase chain reaction (PCR) was done in 35 cycles at 95°C following the first denaturation (95°C for 45 seconds, 60°C for 45 seconds, and 72°C for 60 seconds). The samples were then left at 72°C for the final 4 minutes. Colo-205 cell line DNA, which shows hypermethylation of the p16\textsuperscript{INK4a} gene promoter area, was used as positive control according to the MSP method\textsuperscript{9}. Additionally, DNA extracted from normal skeletal muscles was used as negative control. Each PCR product (10 μL) was loaded on 10% polyacrylamide gel directly, stained with ethidium bromide, and then observed under ultraviolet lights directly.

6. Statistical analysis

Fisher’s exact test was used to analyze the correlation between clinicopathological factors including age, gender, recurrence, and smoking habit according to p16 methylation and immunohistochemical expression of the p16 gene. The chi-square test was used for factors including tumor size, pathological stage, and stage of differentiation. Analysis involving survival rate was done with SAS version 9.13 (SAS Institute, Inc., NC, USA) using the Kaplan-Meier survival curve method\textsuperscript{10} to investigate the survival rate according to p16 methylation and immunohistochemical expression of the p16 gene. The differences in survival rate between the methylation and non-methylation, and between immunohistochemical expression and immunohistochemical non-expression groups were analyzed with log-rank test. The results were considered statistically significant when \( P \)-value<0.05.

III. Results

1. Clinical and histopathological test results

The age range of the 59 patients with head and neck squamous cell carcinoma as the subjects of this study was 28-86 years (average age: 61.8 years); there were 15 women and 44 men. The location of the tumor was mandible for 23 patients, tongue for 11 patients, maxilla for 10 patients, floor of the mouth for 7 patients, buccal cheek for 5 patients, and palate for 3 patients.

The size of the tumor on the first visit based on visual inspection, CT, or MRI imaging was less than 2 cm for 5 patients, less than 4 cm (more than 2 cm) for 25 patients, and more than 4 cm for 19 patients; 10 patients showed impressions of invasion into adjacent structures. Among the study population, 29 patients (49%) had a history of long-term smoking. The investigation of recurrence showed that 48 patients (81%) had no recurrence, and that 11 patients (19%) experienced recurrence. In terms of pathological stage, 3 patients were stage I, 11 patients were stage II, 17 patients were stage III, and 28 patients were stage IV. At least 11 patients showed poorly differentiated cells, 21 patients, moderately differentiated cells, and 27 patients, well-differentiated cells according to the grouping criteria based on cell differentiation. Survival rate was analyzed for all 59 patients.
2. Immunohistochemical test results of p16 protein and statistical correlation (Table 1)

p16 protein was hypo-expressed in 31 tumors (52.5%), and p16 protein expression could be identified in the nucleus and cytoplasm of the remaining 28 tumors (47.5%). (Fig. 1)

Fisher’s exact test results showed that the correlation between age and p16 protein expression was not statistically significant when differentiated according to the mean patient age ($P=1.000$). Likewise, gender ($P=0.561$), recurrence ($P=0.513$), and smoking habit ($P=0.195$) did not have statistically significant correlation. The chi-square test results revealed no statistically significant correlation between p16 protein expression and tumor size ($P=0.129$). Neither was the correlation between pathological stage ($P=0.230$) and level of differentiation ($P=0.817$) statistically significant. (Table 1)

3. Methylation of the promoter area of p16$^{\text{INK4a}}$ gene and statistical correlation (Table 2)

The hypo-expression of p16 protein can occur for various reasons. Thus, we studied the inactivation process of the p16$^{\text{INK4a}}$ gene by investigating the occurrence of methylation. The methylation of p16$^{\text{INK4a}}$ gene was identified in 21 tumors (35.6%), and there was non-methylation in the remaining 38 tumors (64.4%) investigated. (Fig. 2)

### Table 1. Correlations between the immunohistochemical expression of p16 protein and various clinicopathological parameters

| p16 | Non-expression (%) | Expression (%) | $P$-value |
|-----|-------------------|---------------|-----------|
| Age | <avg              | 15 (25.4)     | 13 (22.0) | 1.000$^f$ |
|     | >avg              | 16 (27.1)     | 15 (25.4) | 0.561$^f$ |
| Gender | M                | 22 (37.3)     | 22 (37.3) | 0.513$^e$ |
|      | F                 | 9 (15.3)      | 6 (10.2)  | 0.195$^e$ |
| Recurrence | (-)         | 24 (40.7)     | 24 (40.7) | 0.129$^e$ |
|       | (+)               | 7 (11.9)      | 4 (6.8)   | 0.195$^e$ |
| Smoking | (-)              | 13 (22.0)     | 17 (28.8) | 0.012$^e$ |
|        | (+)               | 18 (30.5)     | 11 (18.6) | 0.230$^e$ |
| Size (cm) | <2            | 5 (8.5)       | 0 (0.0)   | 0.230$^e$ |
|        | ≤4                | 11 (18.6)     | 14 (23.7) | 0.817$^e$ |
|        | ≥4                | 9 (15.3)      | 10 (16.9) | 0.195$^e$ |
| Stage | Inv               | 6 (10.2)      | 4 (6.8)   | 0.195$^e$ |
|       | I                 | 3 (5.1)       | 0 (0.0)   | 0.230$^e$ |
|       | II                | 7 (11.9)      | 4 (6.8)   | 0.195$^e$ |
|       | III               | 9 (15.3)      | 8 (13.6)  | 0.817$^e$ |
|       | IV                | 12 (20.3)     | 16 (27.1) | 0.195$^e$ |
| Differentiation | Poor         | 6 (10.2)      | 5 (8.5)   | 0.230$^e$ |
|         | Mod               | 12 (20.3)     | 9 (15.3)  | 0.195$^e$ |
|         | Well              | 13 (22.0)     | 14 (23.7) | 0.817$^e$ |

(avg: averaged age, M: male, F: female, Inv: invasion, Mod: moderate, $P$-value$^f$: Fisher’s exact test, $P$-value$^e$: chi-square test)

Eui-Hoon Lee et al: Impact of methylation of the p16$^{\text{INK4a}}$ gene on the prognosis of head and neck squamous cell carcinoma patients. J Korean Assoc Oral Maxillofac Surg 2012

### Table 2. Methylation of the promoter area of p16$^{\text{INK4a}}$ gene and statistical correlation

| p16 | Non-expression (%) | Expression (%) | $P$-value |
|-----|-------------------|---------------|-----------|
| S1  | U                  | M             | 154 bp    |
| S2  | U                  | M             | 154 bp    |
| S3  | U                  | M             | 145 bp    |
| C   | U                  | M             | 145 bp    |

(PCR: polymerase chain reaction, S: sample, C: control)

Eui-Hoon Lee et al: Impact of methylation of the p16$^{\text{INK4a}}$ gene on the prognosis of head and neck squamous cell carcinoma patients. J Korean Assoc Oral Maxillofac Surg 2012

Fig. 1. Immunohistochemical staining for p16. In (A), immunohistochemistry shows nuclear/cytoplasmic staining in majority of tumor cells (H&E staining, ×200). In (B), p16 protein expression was not observed in the tumor cells (H&E staining, ×200).

Eui-Hoon Lee et al: Impact of methylation of the p16$^{\text{INK4a}}$ gene on the prognosis of head and neck squamous cell carcinoma patients. J Korean Assoc Oral Maxillofac Surg 2012

Fig. 2. Methylation-specific PCR analysis of p16$^{\text{INK4a}}$ PCR products amplified using unmethylated (U) and methylated (M) specific primers. (PCR: polymerase chain reaction, S: sample, C: control)
Fisher’s exact test results showed no statistically significant correlation between p16\textsuperscript{INK4a} gene methylation and patient’s age (P=1.000). Neither was the correlation between gender (P=0.537), recurrence (P=0.730), and smoking habit (P=0.279) statistically significant. Similarly, the chi-square test results revealed that the relation between gene methylation and tumor size (P=0.491) was not statistically significant; ditto for the correlation between pathological stage (P=0.133) and differentiation level (P=0.682). (Table 2)

4. Correlation between p16 protein expression and methylation

Fisher’s exact test results showed no significant correlation between the methylation of the p16\textsuperscript{INK4a} gene and protein expression based on immunohistochemical methods (P=0.598). (Table 3)

5. Survival analysis

Kaplan-Meier survival analysis was performed according to the expression of p16 protein and methylation of the p16\textsuperscript{INK4a} gene. Log-rank test results between the p16 protein expression and non-expression groups revealed chi-square value of 2.6563 and P-value of 0.1031 (P≥0.05), suggesting that the difference in survival rate was not statistically significant. (Fig. 3) The survival analysis according to the methylation of the p16\textsuperscript{INK4a} gene showed chi-square value of 0.8949 and P-value of 0.6392 (P≥0.05), implying that the methylation of the p16\textsuperscript{INK4a} gene did not have a statistically significant effect on the survival rate in the case of head and neck squamous cell carcinoma. (Fig. 4)

The correlation between survival rate and differentiation level of the tumor was additionally analyzed. The chi-square test results showed chi-square value of 10.740 and P-value of 0.005 (P<0.05), suggesting that the difference in survival rate according to differentiation level was statistically significant.

IV. Discussion

The genetic information of a somatic cell is transferred to the next generation through a series of cell division. This cell division is repeated in cycles, and such replication period is called a cell cycle. This phenomenon consists of a train of regular biological events that follow an exact timetable, which include gene expression and regular changes in protein phosphorylation.

Some factors stimulate cell proliferation, whereas other factors suppress it during the cell growth control process. Growth factors and their receptors and constituents of the mitogen-activated protein kinase pathway stimulate cell growth and division, whereas repressors of the cyclin-cyclin-

**Table 2. Correlations between p16\textsuperscript{INK4a} gene methylation and various clinicopathological parameters**

| Parameter | Non-methylation (%) | Methylation (%) | P-value |
|-----------|---------------------|----------------|---------|
| Age       |                     |                |         |
| <avg      | 18 (30.5)           | 10 (16.9)      | 1.000   |
| >avg      | 20 (33.9)           | 11 (18.6)      |         |
| Gender    |                     |                |         |
| M         | 27 (45.8)           | 17 (28.8)      | 0.537   |
| F         | 11 (18.6)           | 4 (6.8)        |         |
| Recurrence|                     |                |         |
| (-)       | 30 (50.8)           | 18 (30.5)      | 0.730   |
| (+)       | 8 (13.6)            | 3 (5.1)        |         |
| Smoking   |                     |                |         |
| (-)       | 17 (28.8)           | 13 (22.0)      | 0.279   |
| (+)       | 21 (35.6)           | 8 (13.6)       |         |
| Size      |                     |                |         |
| <2        | 4 (6.8)             | 1 (1.7)        | 0.491   |
| <4        | 18 (30.5)           | 7 (11.9)       |         |
| ≥4        | 11 (18.6)           | 8 (13.6)       |         |
| Stage     |                     |                |         |
| I         | 3 (5.1)             | 0 (0.0)        | 0.133   |
| II        | 8 (13.6)            | 3 (5.1)        |         |
| III       | 13 (22.0)           | 4 (6.8)        |         |
| IV        | 14 (23.7)           | 14 (23.7)      |         |
| Differentiation |       |                |         |
| Poor      | 7 (11.9)            | 4 (6.8)        | 0.682   |
| Mod       | 15 (25.4)           | 6 (10.2)       |         |
| Well      | 16 (27.1)           | 11 (18.6)      |         |

(avg: averaged age, M: male, F: female, Inv: invasion, Mod: moderate, P-value\textsuperscript{\textsuperscript{2}}: Fisher’s exact test, P-value\textsuperscript{\textsuperscript{2}}: chi-square test)

**Table 3. Correlations between p16\textsuperscript{INK4a} gene methylation and immunohistochemical expression of p16 protein**

| p16     | Expression       | Non-expression |
|---------|------------------|----------------|
| Methylation |                  |                |
| Non-methylation | 21              | 35.6%          |
| Methylation    | 17              | 28%            |
| Total          | 38              | 52.5%          |

Fisher’s exact test

P-value\textsuperscript{\textsuperscript{2}} = 0.598.
methylation of the DNA base by attachment of a methyl group has huge significance.

Epigenetic modifications such as the methylation of DNA supposedly affect the expression or progression of various tumors. This occurs through the reversible attachment of a methyl group to the 5th carbon of a cytosine in the CpG island, serving as an important process in the development of a normal embryo. When the general hypomethylation of DNA and the abnormal hypermethylation of the tumor suppressor gene promoter area destabilize the chromosome and decrease transcription, however, a selectively advantageous environment for cells of a neoplasm is created.

Hypermethylation of the CpG island near the p16INK4a gene promoter area neutralizes the function of migratory genes such as a transposon that flows in from the exterior and acts as a defense mechanism by the loss of transcription. This is believed to occur by the substitution of methylated cytosine with thymine, which results in the gradual loss of function of migratory genes over time.

Three types of epigenetic information associated with the methylation of genes show high correlation: methylation of DNA, histone modification, and genomic imprinting.

The methylation of DNA is carried out by DNMT. Methylation disturbs the recognition of transcription factors. Once DNA is methylated, "methylated protein" is induced from this region. These proteins attach to factors such as "histone deacetylase" and create a complex. The methylation of DNA suppresses the transcription process by histone modification or chromatin remodeling rather than DNMT activation. Thus, the three different mechanisms—DNA methylation, histone

dependent kinase (CDK) complex, retinoblastoma protein (pRb), and proteins such as p53 suppress it. Most tumors are caused by somatic mutations of cell genes encoding protein products that stimulate or suppress cell growth.

The cell cycle is generally divided into cell division interphase (G1-S-G2) and mitosis (M); at 2 points during this cycle, an all-or-nothing decision is made as to whether a normal cell cycle will proceed or stop. First is the G1 checkpoint, which happens before moving on to S stage from G1 stage; the second point is the G2 checkpoint, which happens before entering the mitosis phase. Among these, pRb, p16, and cyclin D are known as key proteins that control cell growth in the G1 checkpoint.

In particular, the p16INK4a gene is located at 9p21 on the short hand of the ninth chromosome, stopping the process of the cell cycle and encoding a nuclear protein that represses cell growth by bonding with CDK4/6 to interrupt the bonding of cyclin and suppressing CDK activity. When a functional p16 is absent, however, CDK4/6 bonds to cyclin D and phosphorylates pRb, resulting in the release of the transcription factor E2F that stimulates the process of the cell cycle. Many reports have shown such activation in malignant tumors, suggesting that the reduction in p16 expression is related to the progression of tumors and survival rate in many types of tumors. Moreover, the loss of the functional p16INK4a gene is frequently seen in various tumors and malignancies, which probably results from LOH, point mutation, and methylation of the promoter area. From a general genetic viewpoint, the mutation of base substitution is an important phenomenon; in epigenetics, however, methylation of the DNA base by attachment of a methyl group has huge significance.

Epigenetic modifications such as the methylation of DNA supposedly affect the expression or progression of various tumors. This occurs through the reversible attachment of a methyl group to the 5th carbon of a cytosine in the CpG island, serving as an important process in the development of a normal embryo. When the general hypomethylation of DNA and the abnormal hypermethylation of the tumor suppressor gene promoter area destabilize the chromosome and decrease transcription, however, a selectively advantageous environment for cells of a neoplasm is created.

Hypermethylation of the CpG island near the p16INK4a gene promoter area neutralizes the function of migratory genes such as a transposon that flows in from the exterior and acts as a defense mechanism by the loss of transcription. This is believed to occur by the substitution of methylated cytosine with thymine, which results in the gradual loss of function of migratory genes over time.

Three types of epigenetic information associated with the methylation of genes show high correlation: methylation of DNA, histone modification, and genomic imprinting.

The methylation of DNA is carried out by DNMT. Methylation disturbs the recognition of transcription factors. Once DNA is methylated, "methylated protein" is induced from this region. These proteins attach to factors such as "histone deacetylase" and create a complex. The methylation of DNA suppresses the transcription process by histone modification or chromatin remodeling rather than DNMT activation. Thus, the three different mechanisms—DNA methylation, histone
methylation or deacetylation, and chromatin remodeling— are closely related. Moreover, the methylation of DNA maintains gene silence. With demethylation by the removal of DNMT, gene reactivation is observed.

When the chromosomes inherited from the paternal and maternal line all function, there are scores of gene group types that produce genetic defects. In such cases, genes of only one side should be expressed; this control to a proper state is called genomic imprinting. Genes controlled in such fashion are called imprinted genes. However, genetic abnormality occurs when there is loss of imprinting and the imprinted gene appears to be methylated.

Various previous studies have reported the effect of p16INK4a gene methylation on carcinogenesis. Liu et al. measured the level of p16 gene methylation of normal mucosa, leukoplakia, which is a precancerous lesion, and each stage of its cancerous change to oral squamous cell carcinoma and reported that the portion of p16 gene methylation increased with the grade of malignancy of the tissue. Furthermore, the portion of methylated p16 and the portion of p16 protein deficiency by immunohistochemical tests coincided. They stated that p16 could be an important molecular biological marker of cancerous change level of mucosal epithelium and in the diagnosis and progression of oral squamous cell carcinoma. In a similar study, López et al. reported that methylation of the p16 gene was more frequently observed when the level of malignancy was higher at the initial stage of cancerous change.

Similarly, in a study based on the inactivation process of the p16INK4a gene during the cancerous change of rat tongue cells induced by 4-nitroquinoline 1-oxide, Nakahara et al. observed that the methylation of the p16INK4a gene was rare in initial and moderate dysplasia but was frequent in severe dysplasia and squamous cell carcinoma. According to Nakahara, inactivation by the hypermethylation of the p16INK4a gene promoter region is associated with the carcinogenesis of oral cancer.

Gene methylation is observed not only in the p16 gene but also in other genes. Viswanathan et al. studied the methylation of p16, p15, hMLH1, MGMT, and E-cadherin genes associated with oral squamous cell carcinoma and reported that, regardless of the location or pathological stage of the tumor, abnormal methylation did not occur in normal squamous cells but was detected in tumor cells. Viswanathan also stated that the hypermethylation of such genes could be adequately used in the diagnosis of oral squamous cell carcinoma.

In this study, however, the analysis of relations between the immunohistochemical expression of p16 protein and methylation of the p16INK4a gene and various factors showed that age, gender, smoking habit, and recurrence did not have statistical significance; ditto for the relations between pathological stage, size of tumor, degree of histological differentiation, and survival rate. In particular, methylation was observed in 21 of the 59 tissue samples (35.6%), but there was no correlation with the compared factors. According to Okami et al., there was no statistically significant relation between methylation level, pathological impression, and prognosis, but the hypermethylation of genes associated with various types of head and neck cancer plays an important role in carcinogenesis. Furthermore, Koscielny et al. reported that the inactivation of p16 in patients with head and neck squamous cell carcinoma was mainly caused by p16 methylation and loss of heterozigosity, whereas cases of point mutation were rare. The correlation between the resulting p16 inactivation and patient survival, metastasis to lymph nodes, and recurrence of tumor was not statistically significant.

In this study, however, the relation between immunohistochemical p16 expression and methylation of the p16INK4a gene showed that there is p16 protein expression when p16INK4a gene methylation occurs; in some cases, p16 protein is not expressed when p16INK4a gene methylation does not occur. This means that the epigenetic phenomenon of silencing by p16INK4a gene methylation is not the only cause of suppression of p16 gene expression; other genetic variations such as point mutation and loss of heterozigosity also have an effect. Based on the two-hit theory of Knudson, when methylation occurs on only one side of the paired chromosomes, immunohistochemical results may not show total non-expression even when methylation occurs. Many previous studies reported the correlation between the methylation of the CpG island of patients with oral squamous cell carcinoma and p16 protein expression. According to Huang et al., p16 expression decreases as the methylation of the p16INK4a gene increases. On the other hand, Ai et al. reported that the p16INK4a gene was hypermethylated in 27% of the genes, but that the expression of p16 protein was suppressed in 74%. In another study, Ai et al. reported that the hypermethylation of the p16INK4a gene or loss of p16 expression may be referred to as an index of patient survival rate and prognosis evaluation at the initial stage of patients with head and neck squamous cell carcinoma but cannot be used as independent indices of prognosis.
Based on previous studies as well as the results of this study, p16 could be considered methylated in approximately 40% of head and neck squamous cell carcinoma. This implies that p16 methylation cannot be used yet as an index for prognosis evaluation solely but should definitely be considered in the genetic changes of tumor cells along with well-proven factors including the p16/cyclin-dependent kinase/retinoblastoma pathway.

The chi-square test results of this study showed significant correlation between survival rate and histological differentiation level of the tissue (P=0.005). This could be considered an index to verify the reliability of tissue sample extraction and experiment methods applied in this study.

With the development of epigenetics, many studies concerning the methylation of genes are in progress. If the role of gene methylation in carcinogenesis could be proven more clearly, it could be applied in various ways including chemotherapy using demethylating drugs and frozen section biopsy of tissue adjacent to the tumor resected during surgery.

V. Conclusion

The authors investigated the correlation between p16 protein expression and methylation of the p16INK4a gene and various clinical and histopathological factors of patients with head and neck squamous cell carcinoma. A total of 59 tissue samples of patients with head and neck squamous cell carcinoma were used for immunohistochemical tests and tests using MSP. The results were statistically compared and analyzed along with the correlation with survival rate, and the following conclusions were drawn:

1. p16 protein expression could be identified in 28 patients (47.5%), and p16INK4a gene methylation was verified in 21 patients (35.6%).
2. Correlation between age, gender, recurrence, smoking habit, tumor size, pathological stage, and level of tissue differentiation and p16 protein expression was not statistically significant.
3. The methylation of the p16INK4a gene was not significantly correlated with age, gender, recurrence, smoking habit, tumor size, pathological stage, and level of tissue differentiation.
4. p16 protein expression or methylation of the p16INK4a gene was not significantly correlated with survival rate.
5. There was significant correlation between the level of tissue differentiation and survival rate.

The results above show that p16 protein expression and methylation of the p16INK4a gene have an effect on carcinogenesis but cannot be used as an independent index for evaluating prognosis.

References

1. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
2. Santos KF, Mazzola TN, Carvalho HF. The prima donna of epigenetics: the regulation of gene expression by DNA methylation. Braz J Med Biol Res 2003;38:1531-41.
3. Okami K, Sakai A, Onuki J, Hamano T, Iida M, Takahashi M. Promoter hypermethylation of tumor-associated genes in head and neck cancer. Nihon Jibiinkoka Gakkai Kaiho 2005;108:207-13.
4. Dei Tos AP, Maestro R, Doglioni C, Piccinini S, Libera DD, Boiocchi M, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996;148:1037-45.
5. Koscienly S, V Eggerling F, Dahse R. Investigations to the influence of tumor suppressor gene p16 inactivation on the prognosis of head and neck squamous cell carcinoma. Laryngorhinootologie 2004;83:374-80.
6. O'Sullivan B, Shah J. New TNM staging criteria for head and neck tumors. Semin Surg Oncol 2003;21:30-42.
7. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56:3415-20.
8. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995;55:6006-11.
9. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 2001;81:217-29.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
11. Bartkova J, Lukas J, Bartek J. Aberrations of the G1- and G1/S-regulating genes in human cancer. Prog Cell Cycle Res 1997;3:211-20.
12. Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, et al. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol 2003;16:944-50.
13. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
14. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
15. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
16. Weber A, Wittekind C, Tannapfel A. Genetic and epigenetic alterations of 9p21 gene products in benign and malignant tumors of the head and neck. Pathol Res Pract 2003;199:391-41.
17. Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55:2713-8.
18. Bartsch D, Shevlin DW, Callery MP, Norton JA, Wells SA Jr, Goodfellow PJ. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst 1996;88:680-2.
19. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, et al. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene
expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997;3:2229-36.
20. Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011;117:677-87.
21. Liu HW, Hu BQ, Cao CF. The p16 methylation in oral leukoplakia and oral squamous cell carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi 2005;40:94-7.
22. López M, Aguirre JM, Cuevas N, Anzola M, Videgain J, Aguirregaviria J, et al. Gene promoter hypermethylation in oral rinses of leukoplakia patients—a diagnostic and/or prognostic tool? Eur J Cancer 2003;39:2306-9.
23. Nakahara Y, Shintani S, Mihara M, Matsumura T, Hamakawa H. High frequency methylation of p16INK4A gene during 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Oncol Rep 2004;12:101-6.
24. Viswanathan M, Tsuchida N, Shanmugam G. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 2003;105:41-6.
25. Nowak MA, Michor F, Komarova NL, Iwasa Y. Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A 2004;101:10635-8.
26. Huang MJ, Yeh KT, Shih HC, Wang YF, Lin TH, Chang JY, et al. The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. Int J Mol Med 2002;10:551-4.
27. Goldenberg D, Harden S, Masayesva BG, Ha P, Benoit N, Westra WH, et al. Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:39-44.